Scientific rationale for a higher dose of nusinersen

Abstract Objective The long‐term favorable safety profile of nusinersen provides an opportunity to consider a higher dose. We report on the relationships between nusinersen cerebrospinal fluid (CSF) exposure, biomarker levels, and clinical efficacy. Methods The analyses used data from the CS3A and ENDEAR studies of nusinersen in participants with infantile‐onset spinal muscular atrophy (SMA). Steady‐state CSF trough (Ctrough) levels, plasma phosphorylated neurofilament heavy chain (pNF‐H) levels, body weight, and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) scores were selected as parameters of interest. A validated population pharmacokinetic (PK) model was applied to predict the nusinersen CSF Ctrough. PK/pharmacodynamic (PK/PD) models used nusinersen CSF Ctrough measurements, which were time‐matched with CHOP INTEND scores. Results Higher nusinersen CSF exposure was associated with a greater decrease in pNF‐H levels and greater efficacy, as measured by change in the CHOP INTEND score from baseline. These findings indicate a dose–response relationship between CSF nusinersen levels and treatment response. The higher dose is predicted to lead to approximately a 2.4‐fold increase in nusinersen CSF levels with fewer loading doses. PK/PD modeling indicates that a higher concentration of nusinersen may predict an additional 5‐point increase in CHOP INTEND score beyond that observed with 12 mg. Interpretation Our data indicate that a higher dose of nusinersen may lead to additional clinically meaningful improvement in efficacy when compared with the currently approved 12‐mg dose. The efficacy, safety, and PK of a higher nusinersen dose are currently under investigation in the ongoing phase 2/3 DEVOTE study (NCT04089566).